Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

This, international, multi-center, Phase 2 study of verubulin will be conducted in patients
with newly diagnosed Glioblastoma Multiforme (GBM). The study will be conducted in two
parts. Part A is an open-label dose finding study that will determine the safety and
tolerability of verubulin in combination with standard treatment. Part B is a randomized
open-label study that will investigate progression-free survival and overall survival of
patients receiving verubulin, at the dose determined in Part A, in combination with standard
treatment versus standard treatment alone.